Clinical Trials Logo

Persistent Infection clinical trials

View clinical trials related to Persistent Infection.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06339684 Active, not recruiting - Clinical trials for HPV-Related Cervical Carcinoma

HPV Immunological Markers of Cervical Persistent Infection and Oncogenesis

HPVImmuno
Start date: March 8, 2023
Phase:
Study type: Observational [Patient Registry]

The aim of this observational study is to build an immunological assay to quantify an immunoscore system for clinical practice, which could identify HPV lesions with a risk of persistent cervical infection, which represents the main predictive factor of neoplastic evolution. A pattern of host immunological factors and HPV-related parameters, in order to identify an algorithm of risk stratification and tailoring treatment will be identified. Finally, in patients with HPV infection, a virus specific immunity after vaccination will be quantified, in order to highlight those patients who have the most significant risk of infection persistence.

NCT ID: NCT04704908 Active, not recruiting - Cervical Cancer Clinical Trials

Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)

Start date: February 6, 2021
Phase:
Study type: Observational

The primary objective of this study is to evaluate the immuno-persistence (type specific IgG antibody) of the tested vaccine administered in girls aged 9-17 years,comparing to young healthy adults of 18-26 years who received the standard 3-dose schedule (0,1,6 months).

NCT ID: NCT04199689 Active, not recruiting - Clinical trials for Papillomavirus Infections

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Start date: February 27, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the 9-valent human papillomavirus (9vHPV) vaccine in men 20 to 45 years of age. The primary hypothesis tested after the primary database lock is that administration of a 3-dose regimen of 9vHPV vaccine will reduce the incidence of HPV 16/18/31/33/45/52/58-related oral persistent infection (6 months or longer) compared with placebo. There will also be an Extension Study to offer an opportunity to complete the 3 dose regimen of 9vHPV vaccine for participants who received placebo in the Base Study, or received less than 3 doses of 9vHPV vaccine in the Base Study.